

Incomplete
Rev 4/24/87
Complete info. rec'd
5/5/87
DRO
URA

May 5, 1987



Document Control Officer
USEPA/OTS (WH-557)
Chemical Information Division
401 M Street, S.W.
Washington, DC 20460

Dear Sir:

REF: 8EHO-0186-0585S

Per Ms. Cox's request, attached is a sanitized version of the transmittal letter for the data we recently submitted on the subject TSCA 8(e) notice.

CONTAINS NO CBI



8EHQ-0587-0585 ³ Supp.
PDCN: 88-860000059
89-878000007

Document Control Officer
USEPA/OTS (WH-557)
Chemical Information Division
401 M Street, S.W.
Washington, DC 20460

Dear Sir:

REF: 8EHQ-0186-0585S

Attached is a summary of an immunotoxicology study that was recently carried out by . The summary is based on a draft report, but we do not believe that further analysis of the data will change any of the present conclusions. Therefore, we are sending you this notice at this time. You will be sent a final copy of the report when it is received from the investigator, Dr. A. E. Munson, of the Medical College of Virginia.

This study was initiated to further investigate previously-reported immunotoxic effects of Tinuvin[®] 144 (chemical name: bis(1,2,2,-6,6-pentamethyl-4-piperidiny1)(3,5-di-tert-butyl-4-hydroxybenzyl)butyl propanedioate; [63843-89-10]). The previous data, generated by Ciba-Geigy Corporation, were the subject of the initial TSCA § 8(e) Notice of Substantial Risk, 8EHQ-0186-0585S.

considers its interest in this product to be proprietary, even though the data, conclusions, and name of the investigator are not.

Sincerely,

CONTAINS NO CBI